Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance

LAVAL, Quebec, Dec. 15, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Thursday, January 8, 2015 at 8:00 a.m. ET (5:00 a.m. PT) to announce 2015 financial guidance.

The dial-in number to participate on this call is (877) 876-8393, confirmation code 54415766. International callers should dial (973) 200-3961, confirmation code 54415766. A replay will be available approximately two hours following the conclusion of the conference call to January 15, 2014, and can be accessed by dialing (855) 859-2056 or (404) 537-3406, confirmation code 54415766.

The webcast and slide presentation will be hosted in the Investor Relations section of its corporate web site at www.valeant.com. Participants should allow approximately five to 10 minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the internet webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Contact Information:
Laurie W. Little
949-461-6002
[email protected]

Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO

SOURCE Valeant Pharmaceuticals International, Inc.

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.